Economic burden of Huntington disease in Europe and the USA: Results from the Huntington's Disease Burden of Illness study.
Eur J Neurol
; 30(4): 1109-1117, 2023 04.
Article
em En
| MEDLINE
| ID: mdl-36421029
ABSTRACT
BACKGROUND AND PURPOSE:
The prevalence of Huntington disease (HD) has increased over time; however, there is a lack of up-to-date evidence documenting the economic burden of HD by disease stage. This study provides an estimate of the annual direct medical, nonmedical, and indirect costs associated with HD from participants in the Huntington's Disease Burden of Illness (HDBOI) study in five European countries and the USA.METHODS:
The HDBOI is a retrospective, cross-sectional study. Data collection was conducted between September 2020 and May 2021. Participants were recruited by their HD-treating physicians and categorized as early stage (ES), mid stage (MS), or advanced stage (AS) HD. Data were collected via three questionnaires a case report form, completed by physicians who collected health care resource use associated with HD to compute direct medical cost, and optional patient and caregiver questionnaires, which included information used to compute nondirect medical and indirect costs. Country-specific unit cost sources were used.RESULTS:
HDBOI cost estimates were 12,663 (n = 2094) for direct medical costs, 2984 (n = 359) for nondirect medical costs, and 47,576 (n = 436) for indirect costs. Costs are higher in patients who are at later stages of disease; for example, direct medical costs estimates were 9220 (n = 846), 11,885 (n = 701), and 18,985 (n = 547) for ES, MS, and AS, respectively. Similar trends were observed for nondirect and indirect costs. Costs show large variations between patients and countries.CONCLUSIONS:
Cost estimates from the HDBOI study show that people with HD and their caregivers bear a large economic burden that increases as disease progresses.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Huntington
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article